Botanical Extract Characterization
Botanical extract characterization is the technical regime that distinguishes 'standardised extract' (single marker compound at declared %, e.g. milk thistle 80% silymarin) from 'full-spectrum extract' (declared by drug-to-extract ratio, e.g. 4:1 DER, with multi-marker chromatographic profile).
Read the full summary
Under 21 CFR 111.75(a)(1)(i) every botanical component lot must be identity-verified — but identity for a complex botanical extract is more than species confirmation. It includes marker assay, solvent residual, foreign-material screening, and (for premium products) HPTLC chromatographic fingerprint comparison to a reference standard. The single sharpest identity case in the dietary supplement industry, and a recurring §111.75 Warning Letter pattern when shortcuts are taken.
On this page · 6 sections
How does Botanical Extract Characterization apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What botanical extract characterization covers
Botanical extract characterization is the multi-assay identity programme that establishes whether a received botanical-extract component lot matches the intended species, plant part, extraction process, and marker-compound or full-spectrum specification. It is the practical implementation of §111.75(a)(1)(i) identity testing for botanical components, which are inherently more variable and more subject to adulteration than synthetic chemicals.
02Standardised vs full-spectrum extracts
| Attribute | Standardised extract | Full-spectrum extract |
|---|---|---|
| Declaration | Marker compound at declared % (e.g. 80% silymarin) | Drug-to-extract ratio (DER, e.g. 4:1) |
| Identity test | HPLC quantification of marker compound | HPTLC chromatographic fingerprint vs reference standard |
| Pros | Reproducible, marker-traceable, clinical-comparable | Preserves matrix synergy, closer to traditional use, no marker-spiking risk |
| Cons | Risk of marker-only spiking, loses non-marker actives | Higher batch-to-batch variability, harder to standardise label claim |
| Typical use | Premium clinical-positioned products (milk thistle, ginkgo) | Traditional medicine positioning, multi-active botanicals (turmeric, ashwagandha root) |
03The botanical identity assay stack
A defensible §111.75 identity programme for botanical extracts typically uses orthogonal methods:
- Macroscopic — visual inspection of dried plant material (where applicable, pre-extraction). Confirms colour, particle size, texture. Cheapest and fastest first screen.
- Microscopic — light microscopy of plant cells / starch grains / pollen / trichomes. References AHP, USP <2030>, or Ph. Eur. botanical monograph. Confirms anatomical match.
- HPTLC (high-performance thin-layer chromatography) — chromatographic fingerprint pattern matched to a reference standard. AHP and USP monographs publish reference HPTLC patterns. Detects marker AND non-marker adulteration.
- HPLC quantification — quantifies the marker compound % for standardised extracts. Confirms label-claim potency.
- DNA barcoding — PCR-amplified species-specific gene region (ITS, rbcL, matK). Confirms species. Limited for processed extracts where DNA may be degraded.
- Solvent residual — GC-MS for residual extraction solvent (ethanol, methanol, hexane, acetone). USP <467> sets ICH residual-solvent limits.
- Heavy metals — ICP-MS for As, Pb, Cd, Hg per USP <2232>.
- Pesticide residue — GC-MS / LC-MS for pesticide screen per USP <561>.
- Microbial — plate count + pathogen screen per USP <2021>/<2022>/<2023>.
- Foreign material — visual + sieving for contamination (insect fragments, rodent hair, foreign plant material).
04Drug-to-extract ratio (DER) — how full-spectrum is declared
Full-spectrum extracts are declared via DER (drug-to-extract ratio):
- Native DER — ratio of dry plant material to the resulting extract before any added carrier or excipient. A 4:1 native DER means 4 kg dried plant produced 1 kg of pure extract.
- Total DER — ratio after added carrier (maltodextrin, silicon dioxide, etc.). May be lower than native DER. Total DER should be disclosed alongside native if both apply.
- Equivalency — '1 g of 4:1 native DER extract = 4 g of raw plant material' is a common label declaration that requires the DER to be accurate and reproducible.
- Extraction solvent — must be disclosed alongside DER for meaningful interpretation. Water extract, 70% ethanol extract, methanol extract all yield different actives at the same DER.
05Common failure modes
- Single-assay identity — HPLC marker assay only, no orthogonal HPTLC or DNA. Misses marker-spiking adulteration. Most common §111.75 Warning Letter pattern for botanicals.
- Supplier-COA acceptance — relying on supplier COA without independent identity verification. §111.75(a)(1)(i) does not permit this; identity test must be performed by the manufacturer on every received lot.
- Wrong species — supplier ships related species (e.g. Echinacea purpurea instead of Echinacea angustifolia, or American ginseng vs Asian ginseng). Macroscopic and DNA barcoding detect; HPLC marker alone may not.
- Wrong plant part — supplier ships leaf when root was ordered (cheaper, different active profile). Microscopic and chromatographic fingerprint detect.
- Solvent residual exceeded — residual hexane / methanol in extract above ICH Q3C limits. Not detected without GC-MS solvent residual assay.
- Adulteration with synthetic — pharmaceutical compound (e.g. PDE-5 inhibitor in 'natural' sexual-enhancement product) added to botanical extract. USP <2251> screening protocol.
- Heavy-metal load from soil — turmeric, ginseng, and other root botanicals concentrate lead from soil; ICP-MS testing essential.
- DER misrepresentation — supplier declares 10:1 native DER but extraction process actually yields 4:1; buyer pays 10:1 price for 4:1 material. Detectable via reference-extract comparison and total-solids assay.
- Reference standard chain broken — HPTLC reference standard expires or is replaced with non-equivalent material; comparison becomes meaningless.
06How V5 Ultimate handles botanical extract characterization
- Botanical component master: species (Latin binomial), plant part (root / leaf / aerial / seed / etc.), extraction solvent, DER (native + total), standardisation type (standardised / full-spectrum), marker compound, marker % spec.
- Identity assay stack: per-component required assay list (HPLC + HPTLC + DNA + solvent residual + heavy metals + microbial); receipt-to-release workflow blocks at incomplete assay.
- Reference standard register: per-marker reference standard with lot, expiration, COA, supplier, on-site location. Expiration triggers re-purchase + re-validation.
- HPTLC fingerprint baseline: per-component baseline HPTLC pattern stored as image + Rf-value table; new lot compared to baseline; deviation above tolerance flags marker-spiking suspicion.
- Supplier qualification: per-supplier history of identity-test pass rate; suppliers with declining pass rate or repeated adulteration findings flagged for re-audit or de-qualification.
- DNA barcoding outsource: integrates with third-party DNA barcoding lab (Eurofins, Alkemist) with sample-submission workflow + result import.
- BAPP / FDA adulterant intelligence: built-in subscription to American Botanical Council BAPP bulletins; if a known adulterant pattern is reported for a component species, V5 prompts re-verification of recent lots.
- Reserve sample lifecycle: per §111.83/95 reserve sample collected from every received botanical lot + retained one year past expiration + auto-disposal workflow.
- Per-SKU identity audit pack: complete identity dossier (HPLC + HPTLC + DNA + heavy metals + microbial + reserve sample location) per lot per SKU, generated as single PDF for FDA inspection / brand audit.
Frequently asked questions
Q.Is HPTLC mandatory?+
No — but it is the industry best-practice for botanical identity verification. HPLC marker alone is increasingly insufficient to defend against §111.75 Warning Letter scrutiny. AHP and USP monographs publish HPTLC reference patterns precisely because of marker-spiking risk.
Q.Is DNA barcoding required?+
Not regulatorily, but increasingly expected for premium products and for species pairs where adulteration is well-documented (Echinacea, ginseng, Hoodia). DNA barcoding limited for processed extracts where DNA may be degraded; macroscopic + HPTLC remain the work-horses.
Q.Can I rely on the supplier's COA for identity?+
No — §111.75(a)(1)(i) is explicit that the manufacturer must verify identity. Supplier COA is a useful input but cannot substitute for the manufacturer's identity test.
Q.What is the difference between standardised and concentrated extract?+
Standardised = marker compound at declared %. Concentrated = DER expressed (e.g. 10:1). Some products combine both (e.g. '10:1 extract standardised to 5% curcuminoids'). Always disclose both attributes for clarity.
Q.How do I detect marker-spiking?+
HPTLC chromatographic fingerprint vs reference standard; isotope-ratio MS for natural-vs-synthetic origin of the marker compound; AHP / BAPP bulletins for known supplier adulteration patterns; minor-marker screening (presence of non-marker plant compounds expected in the genuine extract).
Q.What is the role of organoleptic testing?+
Visual + taste + smell as preliminary screen — typically by a trained botanical specialist. Catches obvious adulteration cheaply. Cannot replace instrumental methods but is a useful first gate and is documented in many AHP monographs.
Q.Are USP monograph methods mandatory?+
Where a USP monograph exists for a botanical, the USP method is highly defensible. Where no USP monograph exists, AHP monograph or supplier-validated scientifically-valid method (§111.320) is acceptable; method validation evidence must be on file.
Primary sources
- 21 CFR 111.75(a)(1)(i) — Component identity, purity, strength, composition (the 'identity test' obligation)
- USP <565> — Botanical Extracts
- USP <2030> — Articles of Botanical Origin
- USP <2251> — Screening for Undeclared Drugs and Drug Analogues (anti-adulteration testing)
- American Herbal Pharmacopoeia (AHP) — botanical monographs with HPTLC, HPLC, and microscopic identification references
- American Botanical Council — Botanical Adulterants Prevention Program (BAPP) bulletins
Further reading
- Identity testing 111.75(a)(1)(i)Parent regulatory obligation; this page is the botanical-specific deep dive.
- Botanical authenticationOrthogonal identity strategy (HPTLC + DNA + reference standard chain).
- Heavy metals (supplements)Botanical extracts concentrate metals from soil; testing is parallel obligation.
- Economically-motivated adulterationMarker-spiking and full-spectrum substitution are top EMA risks for botanicals.
- Proprietary blendBotanical blends often disclosed only as proprietary; characterization still required internally.
Want to see how Botanical Extract Characterization could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
